Mandated Venous Thromboembolism Prophylaxis. Possible Adverse Outcomes

Journal of Arthroplasty

Volumn 23, Issue 6 SUPPL., 2008, Pages 15-19

  Novicoff, Wendy M ^a   Brown, Thomas E ^a   Cui, Quanjun ^a   Mihalko, William M ^a   Slone, Harris S ^a   Saleh, Khaled J ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

adverse outcomes; pulmonary embolism; venous thromboembolism prophylaxis

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADVERSE OUTCOME; ARTICLE; DEMOGRAPHY; EVALUATION; FEMALE; HEALTH CARE MANAGEMENT; HEMATOMA; HIP ARTHROPLASTY; HUMAN; KNEE ARTHROPLASTY; MALE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; PREVALENCE; PROPHYLAXIS; RETROSPECTIVE STUDY; SEROMA; STATISTICAL ANALYSIS; VENOUS THROMBOEMBOLISM;

ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; FEMALE; FOLLOW-UP STUDIES; GUIDELINES AS TOPIC; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 49549093385     PISSN: 08835403     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arth.2008.04.014     Document Type: Article

References (23)

1. Geerts W.H., Pineo G.F., Heit J.A., et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 338
2. Burnett R.S., Clohisy J.C., Wright R.W., et al. Failure of the American College of Chest Physicians-1A protocol for lovenox in clinical outcomes for thromboembolic prophylaxis. J Arthroplasty 22 (2007) 317
3. Kurtz S., Ong K., Lau E., et al. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 89 (2007) 780
4. Dahl O.E., Caprini J.A., Colwell Jr. C.W., et al. Fatal vascular outcomes following major orthopedic surgery. Thromb Haemost 93 (2005) 860
5. Howie C., Hughes H., and Watts A.C. Venous thromboembolism associated with hip and knee replacement over a ten-year period: a population-based study. J Bone Joint Surg Br 87 (2005) 1675
6. Lie S.A., Engesaeter L.B., Havelin L.I., et al. Early postoperative mortality after 67,548 total hip replacements: causes of death and thromboprophylaxis in 68 hospitals in Norway from 1987 to 1999. Acta Orthop Scand 73 (2002) 392
7. Lieberman J.R., Sung R., Dorey F., et al. Low-dose warfarin prophylaxis to prevent symptomatic pulmonary embolism after total knee arthroplasty. J Arthroplasty 12 (1997) 180
8. Palmer A.J., Koppenhagen K., Kirchhof B., et al. Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thrombo-embolism prophylaxis in orthopaedic surgery: a meta-analysis of randomised clinical trials. Haemostasis 27 (1997) 75
9. Pitto R.P., Hamer H., Heiss-Dunlop W., et al. Mechanical prophylaxis of deep-vein thrombosis after total hip replacement: a randomised clinical trial. J Bone Joint Surg Br 86 (2004) 639
10. Warwick D. New concepts in orthopaedic thromboprophylaxis. J Bone Joint Surg Br 86 (2004) 788
11. Handoll H.H., Farrar M.J., McBirnie J., et al. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures. Cochrane Database Syst Rev 4 (2002) 000305
12. Salvati E.A., Sharrock N.E., Westrich G.H., et al. Three decades of clinical, basic, and applied research on thromboembolic disease after THA. Clin Orthop Relat Res 459 (2007) 246
13. Sculco T.P., Colwell Jr. C.W., Pellegrini Jr. V.D., et al. Prophylaxis against venous thromboembolic disease in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 84 (2002) 466
14. Parvizi J., Ghanem E., Joshi A., et al. Does excessive anticoagulation predispose to periprosthetic infection?. J Arthroplasty 22 (2007) 304
15. American Academy of Orthopaedic Surgeons. Clinical guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty (2007)
16. Beksac B., Gonzalez Della Valle A., and Salvati E.A. Thromboembolic disease after total hip arthroplasty: who is at risk?. Clin Orthop Relat Res 453 (2006) 211
17. Colwell Jr. C.W., Collis D.K., Paulson R., et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 81 (1999) 932
18. Freedman K.B., Brookenthal K.R., Fitzgerald R.H., et al. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am 82 (2000) 929
19. Fitzgerald Jr. R.H., Spiro T.E., Trowbridge A.A., et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty: a randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am 83 (2001) 900
20. Patel V.P., Walsh M., Sehgal B., et al. Factors associated with prolonged wound drainage after primary total hip and knee arthroplasty. J Bone Joint Surg Am 89 (2007) 33
21. Lotke P.A., Palevsky H., Keenan A.M., et al. Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Clin Orthop Relat Res 324 (1996) 251
22. Saleh K.J., Olson M., Resig S., et al. Predictors of wound infection in hip and knee joint replacement: results from a 20 year surveillance program. J Orthop Res 20 (2002) 506
23. SooHoo N.F., Lieberman J.R., Ko C.Y., et al. Factors predicting complication rates following total knee replacement. J Bone Joint Surg Am 88 (2006) 480